*HPLC Determination of Amphetamine and Guanfacine*

HonorsProject

In fulfillmentof the Requirements for The EstherG.

MaynorHonors College UniversityofNorthCarolinaat

Pembroke

By

*Kendra Dorn*

*Department of Chemistry and Physics*

*December 11, 2015*

---

*Name*
Honors College Scholar

12/11/15
Date

---

*Name*
FacultyMentor

12/11/15
Date

---

*Name*
MHC Senior Project Coordinator

12/11/15
Date

**Abstract**:

Stimulant medications are most often prescribed for the treatment of attention deficit hyperactivity disorder (ADHD) and fetal alcohol syndrome (FAS). However, about 20% of the children taking stimulants do not have much symptom relief or they suffer from side effects. As a result, adjunctive therapy is often recommended. One approach is to prescribe Intuniv® (guanfacine) with an ADHD stimulant medication such as Adderall® (amphetamine). Many research studies report that Intuniv® given in combination with a stimulant leads to significant improvements in ADHD and impulsivity symptoms. Therefore, the purpose of this research is to develop an HPLC method to simultaneously determine the concentration of amphetamine and guanfacine in dosage form, which could then be used in the analysis of biological fluids.

**Introduction:**

The research being conducted in this project has not been the only kind done. There has been much research done on the basis of determination or identification of amphetamine and/or guanfacine in biological samples. Throughout all the research, there has been one common motive: develop a method of determination that is effective enough for guanfacine or amphetamine to be quantified in the biological samples. The various methods for determining guanfacine specifically include high-performance liquid chromatography[1,2], spectrofluorimetric determination[3], dried blood spot technology[4], liquid chromatography-tandem mass spectrometry[5], gas chromatography-mass spectrometry[6], and spectrophotometry[7]. The methods for amphetamine are gas chromatography-mass spectrometry[8-12], derivatization and gas chromatography-mass spectrometry[13], liquid chromatography-tandem mass spectrometry[14], liquid chromatography on a chiral stationary phase[15], solid phase extraction and ion-pair

chromatography-electrospray-tandem mass spectrometry[16], pipette tip solid-phase

extraction and gas chromatography-mass spectrometry[17], and the use of a gold

electrode[18]. In all of the previously mentioned methods, separation had been

accomplished, though not all produced it simultaneously. However, obtaining the initial

biological sample that is necessary for most of the methods is largely time consuming and

difficult because access to the samples are extremely limited in part due to the

unwillingness of institutions and medical professionals to share samples with one

another[19].

Guanfacine, which is a non-stimulant, is thought to affect receptors in certain

areas of the brain that strengthen working memory, reduce distraction, and improve

attention and impulse control[20].



**Figure 1**. Structure of Guanfacine Hydrochloride

It is also the main component in Intuniv®. Intuniv is prescribed as a treatment to control

symptoms of attention deficit hyperactivity disorder (ADHD). It can further be prescribed

for high blood pressure.

Amphetamine is a synthetic stimulant of the central nervous system and is used to

increase the synaptic activity of certain neurotransmitters[21]. Although it can be addictive,

it is legally used as part of a treatment plan (along with guanfacine) in treating kids with

ADHD. It works by restoring the balance of natural substances in the brain and helps

with the ability to pay attention, focus, and remain still. Amphetamine is the drug used to

make Adderall® along with dextroamphetamine. It is not only prescribed for helping ADHD, but is also used to treat sleeping disorders and to help people stay awake[22,23].

**Background/Purpose**:

ADHD is the most commonly diagnosed neurobehavioral disorder in children. Symptoms can include hyperactivity, inability to control impulses, and inattention. This disorder mainly affects children, but can continue into adulthood[24]. It is clear the previously noted behaviors can impair and interfere with home life, social settings, and academic performance, but can be subdued through the use of medication. Over the past decade, there has been a dramatic increase in the diagnosis of ADHD. In 2005, according to the National Survey of Children's Health, the percentage of children ages 4-17 years who were diagnosed with ADHD increased from 7.8% to 9.5% during 2003-2007, indicating a 21.8% increase in four years. Furthermore, among children with current ADHD, 66.3% were taking medication. Thus, 4.8% of all children were taking medication (around 2.7 million)[25]. Although it can usually be discovered or diagnosed during a child's early life, how young is too young and are children being diagnosed with insufficient evaluation?

There are various types of ADHD: inattention, hyperactivity, and impulsivity[26]. The different types are categorized based on the severity of the symptoms observed.  For example, a child with inattention may not like to do things the require sitting still, whereas, a child with hyperactivity, rarely remains seated if at all. Nonetheless, the symptoms are all similar, though may vary, as a person gets older. Symptoms can include but are not limited to anxiety, procrastination, mood swings, and depression. A specific cause of ADHD has not been identified, but researchers believe it can be attributed to several things such as heredity, poor nutrition, or chemical imbalances. It cannot be

prevented or cured, but spotting it early on can help ensure proper management of symptoms.

The management of symptoms can be done in the form of medication. Often, stimulants are prescribed to help control the hyperactive and impulsive behaviors, while also increasing the attention span. Some examples include Adderall®, Ritalin®, or Concerta®. Nonetheless, stimulants may not work for every person, or may not work favorably alone. Therefore, non-stimulant medication can be prescribed as well; this is known as adjunctive therapy. Some examples include Intuniv® and Strattera®. Medication is not the only form of treatment that can be used to help manage ADHD. Therapy such as special education or behavior modification can help children learn more efficiently in school and replace inappropriate behavior with good behavior.

For the research being conducted in this experiment, the drugs in focus will include Intuniv® and Adderall®. More specifically, HPLC or high performance liquid chromatography, will be used to simultaneously determine the concentrations of both drugs to further explore how well adjunctive therapy works and how they affect their purpose of treatment.

| Grade Level | Adderall® |
|---|---|
| 8th -graders | 1.80% |
| 10th graders | 4.40% |
| 12th -graders | 7.40% |

Table 1 – Percentage of Students Prescribed Adderall® for ADHD

Adderall® is a commonly prescribed drug to help mange the affects of ADHD. It is a combination of amphetamine and dextroamphetamine. They are central nervous stimulants that affect chemicals in the brain and nerves that contribute to the

hyperactivity and impulsivity experienced by children who suffer from ADHD. It is available either as an immediate release tablet or extended release capsules. It works by increasing the activity of the neurotransmitters norepinephrine and dopamine in the brain[27]. It is generally well tolerated in children and can be effective in treating ADHD symptoms. Specifically, pharmaceutical amphetamines have the potential to improve brain development and nerve growth. Also, they improve stamina, endurance, and reaction time due to effluxion of dopamine in the central nervous system. Studies have also shown that long-term usage of amphetamines can decrease abnormalities in the structure of the brain as well as the function in several areas of the brain. Furthermore, approximately 80% of people who have used this stimulant have seen improvements in ADHD symptoms[28]. If children continue to use stimulant medication, they could have not only better relationships with their family, but also perform better in school and be less distracted.

On the other hand, Intuniv® is similar to Adderall® in its function to help treat ADHD, but it is not a stimulant drug. It is an extended-release form of guanfacine hydrochloride. It has the ability to strengthen parts of the brain that regulate attention and behavior, specifically the prefrontal cortical region[29]. In adjunctive therapy, gaunfacine is used in juxtaposition with stimulants such as amphetamines, to enhance therapeutic actions. While relatively new, it is currently approved and marketed in the U.S. as Intuniv®.

High performance liquid chromatography is basically an improved version of column chromatography. A solvent is forced through a column under high pressures, which makes it extremely quick and efficient. It also allows for the usage of much

smaller particles for the column packing material. This is important because the more small particles that are used increases the surface area which ultimately increases the probability for more interactions between the stationary phase and the mobile phase. This allows for better separation of the components in a mixture[30]. This technique is mostly used in the analytical chemistry field, and as given by the previous description, it is used to separate and identify each component in a mixture. This particular method is imperative to the study being conducted because it is used to "test the products and to detect the raw ingredient used to make them."[31] The biggest benefit from utilizing this method is obtaining a better understanding of the structure, impurities, and degradation, of a drug product that is not just limited to synthetic drugs, but also herbal medications.



**Figure 2.** Actual HPLC instrument used in the experiment

**Figure 3**. Schematic of the HPLC

## Procedure:

Two different forms of guanfacine were used in the experiment: tablet and reference standard (powder).



**Figure 4**. Guanfacine tablet

First, the tablet was made into a solution in order for it to be analyzed by HPLC. The diluent was prepared by mixing 14 mL of water and 6 mL of acetonitrile in a beaker. Next, the guanfacine tablet (2 mg) was crushed into a fine powder. The powder was then dissolved in 10 mL of diluent. Once the solution was both prepared, it was stirred for about ten minutes using a magnetic stir plate due to its low solubility. Next, the dilutions were made: 1:5 (0.04 mg/mL), 1:10 (0.02 mg/mL), 1:20 (0.01 mg/mL), 1:50 (0.004

mg/mL), and 1:100 (0.002 mg/mL). Each dilution was sequentially injected three times into the HPLC instrument.

The guanfacine powder (reference standard) sample preparation began with preparing the solution it would be dissolved in, which is also the diluent. The solution was made by combining 42 mL of water and 18 mL of acetonitrile and mixing well. To dissolve the powder, 50 mL was used for the sample. What was left of the diluent was used to make five more dilutions: (1:5 (0.2 mg/mL), 1:10 (0.1 mg/mL), 1:20 (0.05 mg/mL), 1:50 (0.02 mg/mL), and 1:100 (0.01 mg/mL). As previously done, each sample was injected three times.

## Experimental:

### Chemicals and Reagents
The HPLC mobile phase utilized 80% acetonitrile and 20% 6.25 mM sodium phosphate with a pH adjusted to 3.2 using phosphoric acid (acetonitrile/sodium phosphate source: Fisher Scientific®). The source of both the reference standard and tablets is Sigma Aldrich®.

### Equipment
The HPLC instrument was composed of a pump (Shimadzu DGU-20 AS), a column (Phenomenex Synergi 4u Hydro-RP 80A, 150 x 4.60 mm 4u micron), UV detector (Shimadzu SPD-20A), and Microsoft Excel data system.

### HPLC Method
Through the use of a polar mobile phase of 80% acetonitrile and 6.25 mM sodium phosphate (pH 3.2), the solution was eluted through the column at a flow rate of 0.5 mL/min. The detector was set to a UV wavelength of 220 nm.

## Data/Results:

| | Concen. (mg/mL) | **Tablet**<br>Area | STDEV | RSD | Height | STDEV | RSD |
|---|---|---|---|---|---|---|---|
| | 0.04 | 39648170 | | | 2125587 | | |
| | | 37795629 | | | 2043355 | | |
| | | 41002900 | | | 1955511 | | |
| Average | | 39482233 | 1610061.531 | 4.077939388 | 2041484.333 | 85053.4302 | 4.166254 |
| | 0.02 | 21663334 | | | 1073451 | | |
| | | 22073735 | | | 1223504 | | |
| | | 21918786 | | | 1112119 | | |
| Average | | 21885285 | 207241.364 | 0.946943867 | 1136358 | 77907.7823 | 6.855919 |
| | 0.01 | 4528187 | | | 447245 | | |
| | | 4812862 | | | 452864 | | |
| | | 4740558 | | | 454869 | | |
| Average | | 4693869 | 147969.1216 | 3.152391377 | 451659.3333 | 3952.184248 | 0.875037 |
| | 0.004 | 4279387 | | | 190362 | | |
| | | 4439124 | | | 210064 | | |
| | | 3908031 | | | 212702 | | |
| Average | | 4208847.333 | 272482.7097 | 6.474045935 | 204376 | 12207.94446 | 5.973277 |
| | 0.002 | 1777240 | | | 95516 | | |
| | | 1869122 | | | 84996 | | |
| | | 1883708 | | | 87636 | | |
| Average | | 1843356.667 | 57721.29639 | 3.131314598 | 89382.66667 | 5473.183108 | 6.123316 |

| | Concen. (mg/mL) | **Reference Std**<br>Area | STDEV | RSD | Height | STDEV | RSD |
|---|---|---|---|---|---|---|---|
| | 0.2 | 16181918 | | | 1037437 | | |
| | | 16507459 | | | 962014 | | |
| | | 16758081 | | | 1104165 | | |
| Average | | 16482486 | 288892.1748 | 1.752722101 | 1034538.667 | 71119.80703 | 6.874543149 |
| | 0.1 | 5799404 | | | 423935 | | |
| | | 7252052 | | | 450998 | | |
| | | 7643544 | | | 551735 | | |
| Average | | 6898333.333 | 971622.7438 | 14.08489119 | 475556 | 67346.35493 | 14.16160346 |
| | 0.05 | 4319936 | | | 251576 | | |
| | | 4485695 | | | 261486 | | |
| | | 4575023 | | | 245762 | | |
| Average | | 4460218 | 129437.8327 | 2.90205171 | 252941.3333 | 7950.417935 | 3.143186536 |
| | 0.02 | 1754450 | | | 101863 | | |
| | | 2018195 | | | 110454 | | |
| | | 1969170 | | | 100124 | | |
| Average | | 1913938.333 | 140279.218 | 7.329348892 | 104147 | 5530.79714 | 5.310567889 |
| | 0.01 | 2677565 | | | 149278 | | |
| | | 1277453 | | | 66960 | | |
| | | 1205821 | | | 63778 | | |
| Average | | 1720279.667 | 829806.7202 | 48.23673361 | 93338.66667 | 48471.00207 | 51.93024906 |

Area vs. Concen
ref std

$y = 8E+07x + 394327$
$R^2 = 0.9848$



Height vs. Concen
ref std

$y = 5E+06x + 10444$
$R^2 = 0.9952$

| | | Concen. (mg/mL) | Area | STDEV | RSD | Height | STDEV | RSD |
|---|---|---|---|---|---|---|---|---|
| | | 0.013 | 1153287 | | | 54290 | | |
| | | | 1150687 | | | 56611 | | |
| | | | 1188452 | | | 61300 | | |
| | Average | | 1164108.667 | 21125.12505 | 1.814703872 | 57400.33333 | 3571.037711 | 6.221283926 |
| | | 0.033 | 2630823 | | | 139739 | | |
| | | | 2729841 | | | 148323 | | |
| | | | 2782506 | | | 146640 | | |
| | Average | | 2714390 | 77012.87667 | 2.8372075 | 144900.6667 | 4548.650826 | 3.139151068 |
| | | 0.066 | 6067193 | | | 292853 | | |
| | | | 6402199 | | | 340579 | | |
| | | | 6508095 | | | 322012 | | |
| | Average | | 6325829 | 230158.4803 | 3.638392381 | 318481.3333 | 24058.09582 | 7.554004991 |

**Figure 5** – Guanfacine (0.5 mg/mL) elutes at 4.556 minutes and amphetamine (0.6 mg/mL) elutes at 5.306 min.

## Discussion:

The first set of experimental data was collected from the tablet form of guanfacine. For each of the concentrations, the standard deviation (STDEV) and the relative standard deviation (RSD) was calculated. The calculated values were then used to analyze the data along with the error in the data. The values were suitable for some of the concentrations while others were not, possibly due to some outliers. Because of this error, some modifications need to take place so all the numbers will be more accurate.

The second set of experimental data referred to the reference standard used in the experiment. One concern regarding the table that stood out was the high value of the RSD at 48.2 with the concentration of 0.01. In order to check for possible outliers, a Q test was performed. Once the test was complete, the value calculated was compared to a literature value at the 99% confidence level. While the RSD was abnormally high, it fell within a specified range and was thus determined not to be an outlier. Furthermore, the actual calculation of both the standard deviation and the relative standard deviation helped

examine the accuracy and precision of the measurements taken in the table; it is taught that good precision does not always mean good accuracy. The standard deviation is an indicator of precision based on the reliability of the experimental results while RSD indicates how widely spread the values are from the average. If the standard deviation is high, the results will be seemingly unreliable. It is determined by first calculating the mean. Then, for each number, subtract the mean and square the result. Finally, work out the average of those squared differences. In general terms, precision applies to how well the same measurement was delivered repeatedly, while accuracy applies to how close the results are to the actual measurement. As far as precision is concerned, the RSD for the same concentration repeated in multiples should be below 2%. With a decreased number of samples, a precision of 5-10% RSD is generally accepted. Referring to accuracy, the percent recovery should be within 90-110% (for spiked samples; this is called spiked recovery). These would represent the concentrations not present on the calibration curve. When looking at the linearity of the graphs, it is important to note the correlation coefficient, which a measurement of how accurate a linear relationship is. Ideally, 0.98 or better is best. For both curves comparing the height and areas, the correlation coefficients were within an acceptable range, indicating good measurements. In continuation of the analysis, the height and area were observed as being dependent on the concentration. The calibration curve showed how the height was more accurate than the area. Also, the limit of quantification (LOQ), which is defined as the lowest concentration at which the analyte can be detected (concentrations lower are not within the linear range), was determined to be the 1:50 (0.02 mg/mL) dilution for the reference standard.

The third set of data also concerned the reference standard. The particular set of data was of concentrations between the previously recorded data to verify if the height or area was better use for the calculation of the concentration. This data was also used to calculate the expected concentrations using the calibrations curves. The calculated concentrations were lower than normal, which indicated that some alterations could be done to produce better results.

Finally, Figure 5 is an illustration of what an ideal graph of the concentration of guanfacine and amphetamine would look like if we were successful in simultaneously determining their concentrations.

**Future Work:**

In the future, it would be nice to develop an HPLC method to simultaneously determine guanfacine and amphetamine. The first priority is to find a method to be used for amphetamine that is close in relation to the method used for guanfacine. However, the method for guanfacine needs to be validated and enhanced for acceptable accuracy and precision.

# References:

1) Vinod K. Ahirrao, Dnyaneshwar R. Sangale, Vinayak S. Sonekar, Vinod V. Thorat, Rajendra P. Marathe, Rajesh B. Nawale, and Rajendra P. Pawar: Stability-Indicating RP-HPLC Method for Determination of Guanfacine Hydrochloride in Bulk Drugs and in Pharmaceutical Dosage Form: International Journal of Industrial Chemistry , Vol. 2, Nov. 2, 2011, pp. 69-77

2) Carl E. Wolf, Sara J. Kester-Florin, Alphonse Poklis: A HPLC-MS Method to Detect and Quantify Guanfacine in Urine: Clin Chem Lab Med 2012; 50(3): p. 535-537

3) Abdel-Aziz M. Wahbi, Mona M. Bedair, Shereen M. Galal, Mohamed H. Abdel-Hay, Azza A. Gazy: Spectroflurimetric Determination of Guanethidine Sulphate, Guanfacine Hydrochloride, Guanoclor Sulphate and Guanoxan Sulphate in Tablets and Biological Fluids, Using Benzoin: Mikrochinica Acta 111, 83-91 (1993).

4) Yuanyuan Li, Jack Henion, Richard Abbott, Phillip Wang : Dried Blood Spots as a Sampling Technique for the Quantitative Determiantion of Guanfacine in Clinical Studies : Bioanalysis, Vol. 3, No. 22, pg. 2501-2514.

5) Suryanarayana Murthy Goparaju, Yadagiri Srinivasa Murthy Nandula, Chandrasekher Bannoth Kothapalli, B.R. Challa, Bahlul Z. Awen : Method Development and Validation of Guanfacine in Rat Plasma by Liquid Chromatography- Tandem Mass Spectrometry: Application to a Pharmacokinetic Study : Journal of Pharmaceutical Analysis: 2013: 3(6): 472-480

6) Carrie Haglock, Carl Wolf, Alphonse Poklis : A Novel Method for the Determination of Guanfacine in Urine by Gas Chromatography- Mass Spectrometry : Journal of Analytical Toxicology, 2008; Vol. 32; 544-546

7) G. Nagarjuna Reddy, C. Ramesh, K. Padma Latha, K.V.S. Prasada Rao, B. Ganaga Rao : Assay of Guanfacine in Bulk and its Pharmaceutical Formulations by Extraction Spectrophotometry : An International Journal of Advances in Pharmaceutical Sciences: Vol. 1 (2) Nov-Dec 2010; 327-334

8) J. L. Villamor, A. M. Bermejo, P. Fernandez, M. J. Tabernero :  GC-MS Determination of Amphetamines in Human Urine : Analytical Letters, 38; 781-790, 2005

9) J. L. Villamor, A. M. Bermejo, P. Fernandez, M. J. Tabernero : A New GC-MS Method for the Determination of Five Amphetamines in Human Hair: Journal of Analytical Toxicology, Vol. 29, 135-137

10) Kim Jin Young, Shin Soon Ho, In Moon Kyo : Determination of Amphetamine- Type Stimulants, Ketamine and Metabolites in Fingernail by Gas Chromatography- Mass Spectrometry : Forensic Science Ineternational. 2010, Vol. 194 Issue 1-3, p 108-114

11) Lanickova J, Dedicova M, Vorel F. : Determination of Amphetamine and Methamphetamine in Human Hair using Gas Chromatography / Mass spectrometry : PubMed, Soud Lek. 2000 May; 45 (2): 26-29

12) 	Klette KL, Jamerson MH, Morris-Kukoski CL, Kettle AR, Snyder JJ: Rapid Simultaneous Determination of Amphetamine, Methamphetamine, 3,4-methylenedioxyamphetamine, 3,4- methylenedioxymethamphetamine, and 3,4-methylenedioxyethylamphetmine in Urine by Fast Gas Chromatography-Mass Spectrometry : Journal of Anal Toxicology. 2005 Oct; 29(7): 669-674

13) 	Hallvard Gjerde, Inger Hasvold, Grete Pettersen, Asbjorg S. Christophersen : Determination of Amphetamine and Methamphetamine in Blood by Derivatization with Perluorooctanoyl Chloride and Gas Chromatography/ Mass Spectrometry : Journal of Analytical Toxicology. 1993; Vol. 17: 65

14) 	Maria Jesus Tabernero, Maria Linda Felli, Ana Maria Bermejo, Marcello Chiarotti: Determination of Ketamine and Amphetamines in Hair by LC/MS/MS : Anal Bioanal Chem (2009) 395: 2547-2557

15) 	Alembik MC, Wainer IW: Resolution and Analysis of Enantiomers of Amphetamines by Liquid Chromatography on a Chiral Stationary Phase: Collaborative Study : Journal Assoc Off Anal Chem. 1988 May-Jun; 71 (3): 530-533

16) 	Fuh Ming-Ren, Wu Ti-Yu, Lin Tzuen-Yeuan : Determination of Amphetamine and Methamphetamine in Urine by Solid Phase Extraction and Ion-Pair Liquid Chromatorgraphy- Electrospray-tandem Mass Spectrometry: Talanta. 2006, Vol. 68, 987-991

17) 	Chika Hasegawa, Takeshi Kumazawa, Xiao-Pen Lee, Akemi Marumo, Natsuko Shinmen, Hiroshi Seno, Keizo Sato : Pipette Tip Solid-Phase Extraction and Gas Chromatography – Mass Spectrometry for the Determination of Methamphetamine and amphetamine in Human Whole Blood : Anal Bioanal Chem (2007) 389:563-570

18) 	Maria M. Nevescanin, Milka L. Avramov Ivic, Slobodan D. Petrovic, Dusan Z. Mijin, Sonja N. Banovic Stevic, Vladislava M. Jovanovic : The Use of a Gold Electrode for the Determination of Amphetamine Derivatives and Application to Their Analysis in Human Urine : Journal of Serbian Chemical Society. 78 (9) 1373-1385 (2013)

19) 	Pereira, S. Motivations And Barriers To Sharing Biological Samples: A Case Study. Journal of Personalized Medicine 2013, 3, 102-110.

20) 	David J. Posey, Christopher J. McDougle : Guanfacine and Guanfacine Extended Release: Treatment for ADHD and Related Disoders : CNS Drug Reviews;Vol. 13, No. 4, p. 465-474

21) 	Faculty.washington.edu,. Neuroscience for Kids - Amphetamines https://faculty.washington.edu/chudler/amp.html (accessed Sep 29, 2015).

22) 	MedicineNet.com. dextroamphetamine/amphetamine-oral, Adderall Retrieved  http://www.medicinenet.com/script/main/art.asp?articlekey=45146

23) 	National Institute of Drug Abuse. Stimulant ADHD Meications: Methylphenidate and Amphetamines Retrieved from http://www.drugabuse.gov/publications/drugfacts/stimulant-adhd-medications-methylphenidate-amphetamine

24) 	Goldman, L. Diagnosis And Treatment Of Attention-Deficit/Hyperactivity Disorder In Children And Adolescents. JAMA 1998, 279, 1100.

25) Cdc.gov,. Increasing Prevalence of Parent-Reported Attention-Deficit/Hyperactivity Disorder Among Children --- United States, 2003 and 2007 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5944a3.htm (accessed Oct 4, 2015).

26) DIAMOND, A. Attention-Deficit Disorder (Attention-Deficit/ Hyperactivity Disorder Without Hyperactivity): A Neurobiologically And Behaviorally Distinct Disorder From Attention-Deficit/Hyperactivity Disorder (With Hyperactivity). Develop. Psychopathol. 2005, 17.

27) WebMD,. Adderall oral : Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD http://www.webmd.com/drugs/2/drug-63163/adderall-oral/details (accessed Sep 7, 2015).

28) Lakhan, S.; Kirchgessner, A. Prescription Stimulants In Individuals With And Without Attention Deficit Hyperactivity Disorder: Misuse, Cognitive Impact, And Adverse Effects. Brain Behav 2012, 2, 661-677.

29) RxList,. Intuniv (guanfacine) Drug Overview and Uses for Patients and Caregivers at RxList http://www.rxlist.com/intuniv-drug/consumer-uses.htm (accessed Oct 19, 2015).

30) Chemguide.co.uk,. high performance liquid chromatography - hplc http://www.chemguide.co.uk/analysis/chromatography/hplc.html (accessed Sep 14, 2015).

31) Rasool Hassan, B. HPLC Uses And Importance In The Pharmaceutical Analysis And Industrial Field. Pharm Anal Acta 2012, 03.